Results 11 to 20 of about 566,656 (110)
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
New England Journal of Medicine, 2023 BACKGROUND Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable stage S. Patel, M. Othus, Yuanbin Chen, G. Wright, K. Yost, John R Hyngstrom, S. Hu-Lieskovan, C. Lao, L. Fecher, T. Truong, Jennifer Eisenstein, S. Chandra, Jeffrey A. Sosman, K. Kendra, R. Wu, C. Devoe, G. Deutsch, A. Hegde, Maya Khalil, Ankit Mangla, A. Reese, M. Ross, A. Poklepovic, G. Phan, A. Onitilo, D. Yaşar, Benjamin Powers, G. Doolittle, G. In, Niels Kokot, G. Gibney, M. Atkins, M. Shaheen, J. Warneke, A. Ikeguchi, J. E. Najera, B. Chmielowski, J. Crompton, J. Floyd, E. Hsueh, K. Margolin, W. Chow, K. Grossmann, E. Dietrich, V. Prieto, M. Lowe, E. Buchbinder, John M. Kirkwood, L. Korde, J. Moon, E. Sharon, V. Sondak, A. Ribas +52 moresemanticscholar +1 more sourceMolecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
Nature Medicine, 2023 Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making ...D. Kotani, E. Oki, Yoshiaki Nakamura, H. Yukami, S. Mishima, H. Bando, H. Shirasu, K. Yamazaki, J. Watanabe, M. Kotaka, K. Hirata, Naoya Akazawa, K. Kataoka, Shruti Sharma, V. Aushev, A. Aleshin, T. Misumi, H. Taniguchi, I. Takemasa, T. Kato, M. Mori, T. Yoshino +21 moresemanticscholar +1 more sourceCirculating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
New England Journal of Medicine, 2022 BACKGROUND The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence. J. Tie, J. Cohen, K. Lahouel, S. Lo, Yuxuan Wang, S. Kosmider, R. Wong, J. Shapiro, Margaret Lee, S. Harris, A. Khattak, M. Burge, M. Harris, J. Lynam, L. Nott, F. Day, T. Hayes, S. Mclachlan, B. Lee, J. Ptak, N. Silliman, L. Dobbyn, M. Popoli, R. Hruban, A. Lennon, N. Papadopoulos, K. Kinzler, B. Vogelstein, C. Tomasetti, P. Gibbs +29 moresemanticscholar +1 more sourceAdjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
New England Journal of Medicine, 2021 BACKGROUND Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality.A. Tutt, J. Garber, B. Kaufman, G. Viale, D. Fumagalli, P. Rastogi, R. Gelber, E. de Azambuja, A. Fielding, J. Balmañà, S. Domchek, K. Gelmon, S. Hollingsworth, L. Korde, B. Linderholm, H. Bandos, E. Senkus, J. Suga, Z. Shao, Andrew W. Pippas, Z. Nowecki, T. Huzarski, P. Ganz, P. C. Lucas, N. Baker, S. Loibl, R. McConnell, M. Piccart, R. Schmutzler, G. Steger, J. Costantino, A. Arahmani, N. Wolmark, E. McFadden, V. Karantza, S. Lakhani, G. Yothers, C. Campbell, C. Geyer +38 moresemanticscholar +1 more sourceAdjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
New England Journal of Medicine, 2021 BACKGROUND
No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer.R. Kelly, J. Ajani, J. Kużdżał, T. Zander, E. Van Cutsem, G. Piessen, G. Méndez, J. Feliciano, S. Motoyama, A. Lièvre, H. Uronis, E. Elimova, C. Grootscholten, K. Geboes, S. Zafar, S. Snow, Andrew H. Ko, K. Feeney, M. Schenker, Piotr Kocoń, Jenny Zhang, Lili Zhu, M. Lei, Prianka Singh, K. Kondo, J. Cleary, M. Moehler +26 moresemanticscholar +1 more sourceOverall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Annals of Oncology, 2022 Background: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in ...C. Geyer, J. Garber, R. Gelber, G. Yothers, M. Taboada, L. Ross, P. Rastogi, K. Cui, A. Arahmani, G. Aktan, A. Armstrong, M. Arnedos, J. Balmañà, J. Bergh, J. Bliss, S. Delaloge, S. Domchek, A. Eisen, F. Elsafy, L. Fein, A. Fielding, J. Ford, Sivan Friedman, K. Gelmon, L. Gianni, M. Gnant, S. Hollingsworth, S. Im, A. Jager, O. Johannsson, S. Lakhani, W. Janni, B. Linderholm, T.-W. Liu, N. Loman, L. Korde, S. Loibl, P. Lucas, F. Marmé, E. Martínez de Dueñas, R. McConnell, K. Phillips, M. Piccart, G. Rossi, R. Schmutzler, E. Senkus, Z. Shao, Paramanand Sharma, C. Singer, T. Španić, E. Stickeler, M. Toi, T. Traina, G. Viale, G. Zoppoli, Y. Park, R. Yerushalmi, H. Yang, D. Pang, K. Jung, A. Mailliez, Z. Fan, I. Tennevet, J. Zhang, T. Nagy, G. Sonke, Q. Sun, M. Parton, M. Colleoni, M. Schmidt, A. Brufsky, W. Razaq, B. Kaufman, D. Cameron, C. Campbell, A. Tutt +75 moresemanticscholar +1 more sourcePembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
The Lancet, 2022 BACKGROUND
Pembrolizumab prolongs progression-free and overall survival among patients with advanced melanoma and recurrence-free survival in resected stage III disease.J. Luke, P. Rutkowski, P. Queirolo, M. Del Vecchio, J. Mackiewicz, V. Chiarion-Sileni, L. C. Merino, M. Khattak, D. Schadendorf, G. Long, P. Ascierto, M. Mandalà, F. de Galitiis, A. Haydon, R. Dummer, J. Grob, C. Robert, M. Carlino, P. Mohr, A. Poklepovic, V. Sondak, R. Scolyer, J. Kirkwood, Ke Chen, Scott J. Diede, S. Ahsan, N. Ibrahim, A. Eggermont +27 moresemanticscholar +1 more sourceFive-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
JAMA Oncology, 2022 Importance
Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified FOLFIRINOX vs gemcitabine in patients with resected pancreatic ductal ...T. Conroy, F. Castan, A. Lopez, A. Turpin, M. Ben Abdelghani, A. Wei, E. Mitry, J. Biagi, L. Evesque, P. Artru, T. Lecomte, E. Assenat, L. Bauguion, M. Ychou, O. Bouché, L. Monard, A. Lambert, P. Hammel, Eric Francois, Jean-François Ramee, Hélène Castanie, Marc Pracht, François Ghiringhelli, Emmanuel Maillard, Caroline Couffon, Julien Volet, Vincent Bourgeois, Marion Chauvenet, J. Blanc, Denis Péré-Vergé, C. de la Fouchardiére, Antoine Adenis, Farid El Hajbi, Jaafar Bennouna, Patrick Texereau, Roger Faroux, Laurent Miglianico, Christian Platini, Jean-Louis Legoux, François-Xavier Caroli-Bosc, Karine Bouhier-Leporrier, Alice Gagnaire, Victoire Granger, Valérie Lebrun-Ly, Rosine Guimbaud, Yann Touchefeu, M. Gasmi, Frédéric Di Fiore, Jean François Seitz, P. Etienne, Catherine Ligeza Poisson, Yves Rinaldi, Nabil Baba-Hamed, J. Bachet, Thomas Aparicio, Laurence Chone, Marielle Guillet, Julien Forestier, Eric Terrebonne, Mohamed Hebbar, Gilles Breysacher, Thierry André, Faiza Khemissa-Akouz, Vincent Hautefeuille, Véronique Guerin-Meyer, Johannes Hartwig, Yves Becouarn, David Malka, Christophe Louvet, Jean-Luc Raoul, Laurent Cany, Beata Juzina, Claire Jouffroy, Sophie Gourgou, Mohammad Rassouli, Haji Chalchal, Daniel Renouf, Ralph Wong, F. Lemay, F. Aubin, Felix Couture, Elaine Mc Whirter, Stephen Welch, Petr Kavan, Brian Findlay, Christine Cripps, P. Cano, Shahid Ahmed, Mohammed Harb, Bryn Pressnail, Scott Dowden, Chris O'Callaghan +91 moresemanticscholar +1 more sourceBiomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
Journal of Clinical Oncology, 2022 PURPOSE To update recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer.F. André, Nofisat Ismaila, K. Allison, W. Barlow, Deborah E. Collyar, S. Damodaran, N. L. Henry, K. Jhaveri, K. Kalinsky, N. Kuderer, A. Litvak, E. Mayer, L. Pusztai, R. Raab, A. Wolff, V. Stearns +15 moresemanticscholar +1 more source
